William Blair has reaffirmed its stock rating for Cullinan Oncology following the release of new trial data. The firm’s analysis indicates that the data supports the company's ongoing research and development efforts in oncology. Investors and market analysts are closely monitoring the implications of this trial data on Cullinan Oncology's future performance and strategic direction.
Don't miss out on breaking stories and in-depth articles.
